Another marker of this trend is the FORWARD-3 trial of buprenorphine (mu-opioid receptor partial agonist and kappa opioid receptor antagonist) plus samidorphan (mu-opioid receptor antagonist) in MDD, which did not outperform placebo, despite positive phase 2 study results. Here, OPRM1 is linked to major depressive disorder.